explore -WSS

explore

author：comprehensive 2025-08-31 01:56:26 - browse：4

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

WSS

First transplant of an entire human eye performed

Weight loss drugs should be covered by insurers, AMA says

A letter from the executive editor: STAT UnitedHealth investigation

UnitedHealth sued over use of algorithm in Medicare Advantage plans

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Healthy food access boosts outcomes in two studies

knowledge

explore

knowledge

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

New air purifier tech could be key to improving indoor air quality

How state and local governments are sidelining science

23andMe had bad news about my health. I wish a person had delivered it

Ohio still needs to do more to protect the right to abortion

Drug repurposing or repositioning? The language matters

Medical school prerequisites are outdated

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Publishing genetic code of viruses could cause disaster

explore

UnitedHealth sued over use of algorithm in Medicare Advantage plans

CVS, Rite Aid closures threaten to worsen pharmacy deserts

UnitedHealth sued over use of algorithm in Medicare Advantage plans

UnitedHealth sued over use of algorithm in Medicare Advantage plans

What is STAT's opinion section for?

What is STAT's opinion section for?

hotspot

Wikipedia

leisure time

focus